Company Overview and News
“We are excited to enter this expression of interest to work with CSCEM, the Malaysian arm of one of the world’s largest construction companies, on the RTS project,” said DRealty group chief executive officer Brian Iskandar Zulkarim(pic).
Damansara Realty Bhd chief executive officer Brian Iskandar Zulkarim. — dbhd.com imageKUALA LUMPUR, Feb 13 — Damansara Realty Bhd recorded a net profit of RM17.8 million for its financial year ended Dec 31, 2017 following three years of losses including RM27.8 million in the previous year.
Group chief executive officer Brian Iskandar Zulkarim(filepic) said education was urgently needed on the importance of proper building maintenance and management to ensure a safe as well as healthy environment for the people.
KUALA LUMPUR: JF Apex Research expects Damansara Realty , Kimlun, MCE and George Ken to be among the stocks to watch on Friday following their latest corporate news.
KUALA LUMPUR: JF Apex Research expects Damansara Realty , AirAsia , FoundPac and MISC to be among the stocks to watch on Tuesday following their corporate news.
PETALING JAYA: After five years of losses, O&C Resources Bhd’s (OCR) turnaround plan appears to be on track, with both its earnings and orderbook replenishment being on the uptrend.
Massive project: A panoramic view of Forest City during sunset. The whole project is expected to take more than 20 years to complete.
Pahang State Executive Councillor for Health, Human Resources and Special State Duties Datuk Norol Azali Sulaiman and Damansara Realty Bhd group CEO Brian Iskandar Zulkarim at the launch of the project on Saturday.
KUALA LUMPUR (March 10): theedgemarkets.com highlighted 15 stocks with momentum at Bursa Malaysia’s afternoon market close today. There were 14 stocks with negative momentum, while one stock displayed positive momentum.
KUALA LUMPUR (March 10): The FBM KLCI dipped at the midday break today as sellers outpaced buyers, underpinned by tepid sentiment at the local market.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...